Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesSleep MedicineeviCore Sleep Disordered Breathing Coverage Update…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentevicorePolicy N/A

    Sleep Disordered Breathing Diagnosis and Treatment Guidelines

    Customize your policy alerts

    Sign up for all evicore policy alerts

    Know when evicore releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Clinical coverage guidelines governing diagnostic testing and treatment criteria for sleep-related breathing disorders for health plans administered by Cigna and implemented by eviCore; affects clinicians ordering or interpreting sleep studies and related services.

    Policy Summary
    Payerevicore
    PolicySleep Disordered Breathing Diagnosis and Treatment Guidelines
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateNov 5, 2026
    Next Review DateNov 5, 2026
    Key ActionHSAT and/or PSG must be ordered by a treating medical provider and interpreted by a board-certified sleep medicine physician or a provider overseen by one.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    ≥15OSA diagnostic threshold
    5–14Mild OSA range
    ≥5CSA central index
    ≥4 hrsPAP adherence
    30 daysCompliance period
    ≥10%Weight change trigger

    Coverage Criteria — Diagnostic Testing and Therapies

    Pre-test clinical criteria for sleep diagnostic testing

    Covered when ALL of the following are met

    Clinical evaluation: A current comprehensive clinical evaluation by the treating medical provider (face-to-face or telehealth) including documentation of sleep symptoms and relevant physical examination elements is present

    Includes sleep history, physical exam, relevant diagnostics/labs (ABG or serum bicarbonate within one year)

    Sleep symptom documentation: Documentation of sleep-related signs or symptoms relevant to suspected diagnosis OR results/ability to calculate a validated sleep questionnaire

    Questionnaires include STOP-BANG, Berlin, ISI, Epworth; prior diagnosis of OSA with prior testing can substitute

    Prior testing attempt: Reasonable attempt to obtain prior sleep testing results documented prior to requesting repeat testing

    Attempts include contacting prior facility/provider, DME supplier, or asking patient for prior results

    Policy Summary
    Payerevicore
    PolicySleep Disordered Breathing Diagnosis and Treatment Guidelines
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateNov 5, 2026
    Next Review DateNov 5, 2026
    Key ActionHSAT and/or PSG must be ordered by a treating medical provider and interpreted by a board-certified sleep medicine physician or a provider overseen by one.
    SourceLink
    On This Page
    Coverage Criteria — Diagnostic Testing and TherapiesCoding — Procedure and Supply CodesProvider Actions — Ordering, Documentation, and AuthorizationBackground and ScopeDefinitions and Diagnostic ThresholdsRevision History and References

    Diagnostic thresholds for OSA diagnosis

    OSA diagnosis criteria: Predominantly obstructive AHI or RDI on PSG, or AHI or REI on HSAT ≥15 events/hour>=15 events/hour
    Mild OSA with symptoms/comorbidity: Predominantly obstructive AHI or RDI on PSG, or AHI or REI on HSAT ≥5 and <15 events/hour with documentation of symptoms (sleepiness, awakenings with gasping) or comorbidity (hypertension, mood disorder, coronary artery disease, congestive heart failure, atrial fibrillation, type 2 diabetes mellitus, stroke)5-14.9 events/hour

    Diagnostic thresholds for Central Sleep Apnea (CSA)

    Covered when ALL of the following are met

    Symptoms present: Presence of one or more symptoms: sleepiness; difficulty initiating or maintaining sleep; frequent awakenings or non-restorative sleep; awakening short of breath; witnessed apneas
    Central events threshold: Central apnea and/or central hypopnea index ≥5 per hour>=5 events/hour

    Central apneas plus central hypopneas constitute >50% of total apneas and hypopneas

    HSAT vs PSG / In-lab testing indications

    HSAT is medically necessary for adults when clinical evaluation raises concern for OSA unless one or more PSG indications are met.

    HSAT appropriateness: HSAT is medically necessary when clinical evaluation leads to concern for OSA in adults

    HSAT preferred for initial evaluation of uncomplicated suspected OSA

    Indications requiring PSG rather than HSAT

    • Low-risk questionnaire or inability to rely on HSAT selection: Results of a validated questionnaire (eg, STOP-BANG or Berlin), or history/physical permitting completion, indicating low risk such that HSAT is inappropriate

      See Questionnaires (SL-8)

    • Inability to use HSAT safely: Individual lacks mobility, dexterity, or cognitive ability to use HSAT safely at home

      Documented in record

    • Prior HSAT non-diagnostic: Prior HSAT showed AHI <5 using 3% hypopnea rule (per submitted report)AHI <5 (3% rule)

      Submitted prior report required

    • Prior HSAT technically inadequate: Prior HSAT lacked at least 4 hours of adequate oximetry and flow data (per submitted report)<4 hours adequate oximetry/flow

      Submitted prior report required

    • Obesity with gas-exchange concerns: Obesity with BMI ≥45 OR BMI ≥30 plus awake ABG/EtPCO2/TcPCO2 PCO2 ≥45 OR BMI ≥30 plus serum bicarbonate ≥27 with concern for OHSBMI and gas values as stated

      Indicates need for in-lab evaluation

    • Moderate to severe pulmonary disease: Nocturnal oxygen use OR ABG PO2 <60 or PCO2 ≥45 OR PFTs with FEV1 ≤69% predictedas stated

      Consider in-lab testing

    • Documented neurological disease or concern for central apnea/hypoventilation: Neurological disease that precludes HSAT use OR concern for central apnea/hypoventilation (eg neuromuscular disease)

      Documented in clinical notes

    • Moderate to severe heart failure: Documented pulmonary congestion or left ventricular ejection fraction <45%LVEF <45%

      In-lab testing indicated

    • Pulmonary hypertension: Mean pulmonary artery pressure >20 mmHg on right heart catheterization or echocardiographic surrogates (eg TR velocity ≥2.9 m/s)mPAP >20 mmHg

      In-lab testing indicated

    • Chronic severe insomnia: Documented severe insomnia (Insomnia Severity Index ≥22)ISI ≥22

      In-lab testing may be required

    • Chronic daily opioid use with CSA concern: Daily long-acting opioid use OR daily opioid use plus stated concern for central sleep apnea

      Documented opioid use and CSA concern

    • Requirement for bilevel titration or specific disorders: Bilevel PAP (E0470/E0471) specifically requested for central sleep apnea, treatment-emergent CSA, neuromuscular disease, severe COPD (PaCO2 ≥52 mmHg), OHS, or other hypoventilation conditionsPaCO2 ≥52 mmHg for severe COPD where indicated

      In-lab full night PAP titration required

    • Sustained oxygen desaturation: Sustained oxygen saturation ≤88% for at least 5 total minutes independent of respiratory events on prior studySaO2 ≤88% ≥5 minutes

      Documented on prior facility or HSAT report

    • Prior unsuccessful APAP trial: APAP trial ≥30 days with either download showing AHI ≥5 with ongoing symptoms, or APAP use ≥4 hours/night on 70% nights with continued symptoms, or intolerance despite interventions30-day APAP trial; adherence criteria apply

      APAP trial required before certain in-lab titration requests

    ref':'b0_4
    title':'HSAT vs PSG / In-lab testing indications'
    title_error_fix_me? Please note this string contained single quotes causing JSON invalidity

    Sleep diagnostic testing is covered only when a comprehensive clinical evaluation by the treating medical provider is documented, including relevant sleep symptoms, focused exam findings, and an attempt to obtain prior sleep study results when applicable. Routine or indiscriminate testing is discouraged: testing solely for isolated insomnia or for asymptomatic pre‑operative screening (e.g., prior to bariatric surgery) is not medically necessary unless other qualifying signs/symptoms or comorbidities are present. Requests for repeat testing must show that results would change management and not be duplicative of recent adequate studies. Evidence of prior tests and a clear clinical rationale must be submitted to avoid denial for redundant testing.

    Polysomnography is not medically necessary for routine evaluation of typical disorders of arousal (e.g., sleep terrors, confusional arousals, sleepwalking) or for isolated parasomnia phenomena unless there is documented concern for safety, injurious behaviors, or nocturnal seizures. For pediatric patients, uncomplicated parasomnias likewise do not typically require PSG unless other comorbidities or safety concerns exist; documentation must include a complete description, assessment, and rationale when PSG is requested for atypical or potentially injurious parasomnias.

    In the absence of safety concerns or suspicion for nocturnal seizures, PSG is not medically necessary for the evaluation of common parasomnias (nightmares, sleep talking, bruxism, isolated sleep starts) or typical arousal disorders. When REM behavior disorder or suspected PLMD is being considered, a clear description of dream‑enacting behaviors or limb movement–related impairment is required to justify in‑lab testing; otherwise, HSAT should be considered for uncomplicated presentations.

    Requests for PSG that rest solely on routine symptoms without documentation of safety risk, nocturnal seizure concern, or other listed comorbid indications may be denied. The policy emphasizes obtaining prior study results and ensuring that repeat or additional testing will impact management; routine repeat PSG or HSAT without a documented clinical change or adequate justification is not supported.

    PSG is not medically necessary for isolated conditions listed in the guidelines (e.g., sleep talking, isolated nightmares, exploding head syndrome, recurrent isolated sleep paralysis) unless the record documents a safety risk or concern for nocturnal seizures. For pediatric evaluations, routine PSG is not indicated for uncomplicated adenotonsillar hypertrophy or resolved mild OSA following adenotonsillectomy unless new symptoms or risk factors appear.

    Repeat diagnostic or titration testing is not medically necessary when the sole purpose is to obtain equipment replacement or to supply new PAP devices/supplies. Replacement or repeat studies require documentation of a clinically meaningful change (for example, ≥10% weight change, recurrence of symptoms, or inadequate prior study) and prior attempts to obtain prior reports; mere equipment needs or aging alone do not justify repeat sleep testing.

    Aging by itself is not a supported indication for repeat diagnostic sleep testing. The literature and guideline review indicate that changes in respiratory event indices over time are more strongly associated with weight change and comorbidities than with chronological age; therefore repeat testing should be tied to clinical change rather than age alone.

    Sleep testing of asymptomatic individuals solely to initiate or continue pharmacologic anti‑obesity therapy (Zepbound/tirzepatide) is not medically necessary. Repeat studies to continue or resume Zepbound are likewise not supported; reassessment of OSA severity in the context of weight‑loss drug therapy should follow the policyʼs repeat testing criteria (e.g., significant weight change or other clinical triggers).

    Home/portable sleep studies for the diagnosis of OSA in children (≤17 years) are considered experimental, investigational, or unproven because they lack reliable CO2 and arousal monitoring and cannot reliably exclude OSA or determine severity. Pediatric diagnostic evaluation generally requires in‑lab polysomnography (CPT 95782/95783) when indicated by symptoms or specific risk factors; HSAT is not sufficient for initial pediatric diagnosis except in very limited, well‑documented circumstances.

    The inclusion of codes in the treatment and coding tables is informational and does not imply that a code is managed by or requires prior authorization from a specific health plan. Providers must consult the applicable health plan for plan‑level prior authorization requirements — listing a CPT/HCPCS code in this guidance does not guarantee coverage or payment.

    For severe COPD, formal sleep testing may not be required to initiate ventilatory support when physiologic criteria are met; however, the policy requires that OSA and CPAP treatment have been considered and ruled out prior to approving bilevel therapy for COPD‑related hypoventilation. Objective physiologic documentation (e.g., awake PaCO2 ≥52 mmHg) and clinical rationale are necessary when requesting bilevel devices for COPD indications.

    Requests to replace a PAP device will be denied if the device remains under the manufacturer warranty or if the DME supplier has not physically evaluated the device and determined it cannot be repaired. Replacement approvals require evidence of continued device use (compliance), demonstration that the device is non‑operational, DME evaluation documentation, and confirmation that warranty coverage has expired.

    The policy lists specific therapies and devices considered experimental, investigational, or unproven (e.g., Bongo Rx, ULTepap, iNAP, eXciteOSA HCPCS E0492/E0493, Somnera, MATRx oral appliance test, HCPCS E0530 electronic positional therapy). Stand‑alone actigraphy (CPT 95803) and PAP‑NAP (CPT 95807/95807‑52) are also not covered. Use of nonspecific DME codes (CPT 94799, HCPCS E1399) for routine PAP machines and supplies is discouraged and may be denied when more specific codes exist.

    Actigraphy performed as a stand‑alone diagnostic study (CPT 95803) is considered not medically necessary. Likewise, PAP‑NAP (CPT 95807 or 95807‑52) is explicitly not covered due to insufficient controlled evidence; routine use of CPT 94799 or HCPCS E1399 for standard PAP devices and supplies will not be approved when specific HCPCS/CPT codes apply.

    This section cites multiple CMS Local Coverage Determinations (LCDs) and industry regulatory references that inform device‑ and procedure‑specific coverage considerations (for example, hypoglossal nerve stimulation and respiratory assist device LCDs) as well as FDA PMA/SSED documents for implantable devices. These references may be relevant to prior authorization reviews and device‑specific requirements but do not by themselves define new coverage criteria in this guidance.

    A key denial trigger is requesting additional or duplicate testing when the same or similar studies have already been performed without a clear clinical rationale tied to guideline criteria. Repeat diagnostic or titration studies submitted solely for equipment replacement, routine surveillance of asymptomatic individuals, or without documentation of clinical change are subject to denial. Providers must document attempts to obtain prior study reports when they exist; failure to do so can also prompt denial.

    Coding — Procedure and Supply Codes

    PAP device HCPCS referenced for titrationHCPCS
    E0470Bilevel positive airway pressure, non-invasive (single-limb), with backup rate (example HCPCS referenced for equipment request)
    E0471Bilevel positive airway pressure, non-invasive (single-limb), without backup rate (example HCPCS referenced for equipment request)
    Home Portable Monitoring (HSAT) HCPCSHCPCS
    G0398Home sleep study (HSAT) with type II portable monitor, unattended
    G0399Home sleep test (HSAT) with type III portable monitor, unattended
    G0400Home sleep test (HSAT) with type IV portable monitor, unattended
    PSG procedure codes for unattended sleep studies (CPT)CPT
    95800Sleep study, unattended, simultaneous recording
    95801Sleep study, unattended, simultaneous recording
    95806Sleep study, unattended, simultaneous recording — do not report in conjunction with certain codes
    Attended polysomnography and sleep studies (CPT)CPT
    95805MSLT or MWT; recording, analysis and interpretation
    95807Sleep study with PAP titration (may be considered experimental/investigational when 95807 or 95807-52 is used to request a PAP-NAP)
    95808Polysomnography; (any age) sleep staging with 1-3 additional parameters, attended
    95810Polysomnography; (any age) sleep staging with 4+ additional parameters, attended (in-lab full night diagnostic)
    95811Polysomnography with initiation of CPAP or Bi-level ventilation OR split-night study / full night PAP titration
    Pediatric attended polysomnography codesCPT
    95782Polysomnography, younger than 6 years, sleep staging with 4+ additional parameters of sleep, attended by a technologist (in-lab full night diagnostic)
    95783Polysomnography, younger than 6 years, with initiation of continuous positive airway pressure therapy or bi-level ventilation (in-lab full night PAP titration)
    Pediatric PSG CPT CodesCPTCovered
    95782Polysomnography, (younger than 6 years), sleep staging with 4 or more additional parameters of sleep, attended by a technologist (in-lab full night diagnostic)
    95783Polysomnography, (younger than 6 years), sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist (in-lab PAP titration)
    Bilevel PAP HCPCS referenced for titrationHCPCS
    E0470Bilevel positive airway pressure, non-invasive (single-limb), with backup rate (example HCPCS referenced for equipment request)
    E0471Bilevel positive airway pressure, non-invasive (single-limb), without backup rate (example HCPCS referenced for equipment request)
    PSG CPT Codes mentioned in context of MSLTCPT
    95810Polysomnography; attended
    95811Polysomnography; attended with initiation of continuous positive airway pressure therapy or bi-level ventilation
    Durable medical equipment code referenced for APAPHCPCS
    E0601Continuous positive airway pressure (CPAP) device, standard (used as example in guidance)
    Referenced HCPCS codes for bilevel PAPHCPCS
    E0470Bi-level PAP, fixed CPAP code referenced in context of requesting bi-level PAP titration
    E0471Bi-level PAP, spontaneous/timed referenced in context of requesting bi-level PAP titration
    Treatment HCPCS - PAP devicesHCPCS
    E0601Continuous airway pressure (CPAP/APAP) device
    E0470Respiratory assist device, bi-level pressure (BPAP) capability, WITHOUT backup rate feature, used with noninvasive interface
    E0471Respiratory assist device, bi-level pressure (BPAP) capability (including ASV), WITH backup rate feature, used with noninvasive interface
    E0472Respiratory assist device, bi-level pressure (BPAP) capability, WITH backup rate feature, used with invasive interface (tracheostomy)
    E0561Humidifier, non-heated, used with PAP device
    Treatment HCPCS - PAP interfaces & accessoriesHCPCS
    E0562Humidifier, heated, used with PAP device
    A4604Tubing with heating element
    A7027Combination oral/nasal mask
    A7028Replacement oral cushion combo mask
    A7029Replacement nasal pillow comb mask
    A7030CPAP full face mask
    A7031Replacement facemask interface
    A7032Replacement nasal cushion
    A7033Replacement nasal pillows
    A7034Nasal interface (mask or cannula) used with PAP device
    1–10 of 18
    1/2
    Treatment codes - Monitoring and managementmixed
    A9279Monitoring feature/device, stand-alone or integrated (compliance/data download)
    94660CPAP initiation and management (patient instruction at therapy start)
    Covered HCPCS for CPAP/APAPHCPCSCovered
    E0601Continuous Positive Airway Pressure (CPAP) / Auto-Adjusting Positive Airway Pressure (APAP)
    Covered HCPCS for Bi-level PAPHCPCSCovered
    E0470Bi-level Positive Airway Pressure, spontaneous mode (Bilevel PAP)
    Covered HCPCS for Bi-level PAP with backup/timed featuresHCPCSCovered
    E0471Bi-level PAP, spontaneous/timed mode or ventilatory support (Bilevel PAP with timed or backup rate / indications include central sleep apnea, neuromuscular disease)
    Referenced HCPCS codesHCPCS
    E0471Adaptive servo ventilation (ASV) / PAP therapy (ASV referenced for initiation, continuation, replacement)
    E0470Bilevel PAP (referenced as bilevel HCPCS)
    E0601CPAP device (referenced)
    E0562Heated humidifier
    E0561Non-heated humidifier
    Referenced CPT codesCPT
    94660Physician face-to-face service addressing PAP usage (mask adjustment, pressure titration, PAP-related service)
    PAP initiation/management CPTCPT
    94660Physician face-to-face service addressing PAP usage (application or adjustment of mask or pressure titration or PAP related service)
    Covered PAP supplies HCPCSHCPCSCovered
    A7027Combination oral/nasal mask, used with PAP, each
    A7028Oral cushion used with combination oral/nasal mask, replacement only
    A7029Nasal pillows used with combination oral/nasal mask, replacement only, pair
    A7030Full face mask used with PAP, each
    A7031Full face mask interface replacement, each
    A7034Nasal interface (mask or cannula type) used with PAP, each
    A7032Cushion for use on nasal mask interface, replacement only, each
    A7033Nasal pillow for use on nasal cannula type interface, replacement only, pair
    A7044Oral interface used with PAP, each
    A7035Headgear used with PAP, each
    1–10 of 17
    1/2
    Oral appliance treatment codesHCPCS
    E0485Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, prefabricated, includes fitting
    E0486Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment
    A9270Non-covered item or service (used for oral appliances that do not incorporate all policy criteria; tongue-retaining or tongue-positioning devices; devices used only to treat snoring without OSA)
    K1027Oral device/appliance used to reduce upper airway collapsibility, without fixed mechanical hinge, custom fabricated, includes fitting
    Excluded or discouraged codesmixedNot Covered
    94799Unlisted pulmonary service or procedure (not approved for routine PAP-related services when more specific codes exist)
    E1399Miscellaneous durable medical equipment items, components, and accessories (not approved for routine PAP supplies when more specific codes exist)
    E0530Electronic positional obstructive sleep apnea treatment with sensor (listed among therapies with unestablished effectiveness)
    Stand-alone sleep testing excludedCPTNot Covered
    CPT 95803Actigraphy
    PAP-NAP not coveredCPTNot Covered
    CPT 95807PAP-NAP (daytime abbreviated cardiorespiratory sleep study)
    CPT 95807-52PAP-NAP (reduced service)
    DME exclusions / limited approvalmixedNot Covered
    CPT 94799Unlisted pulmonary service or procedure
    HCPCS E1399Miscellaneous durable medical equipment items, components, and accessories
    Devices listed as experimental/unprovenHCPCSExperimental
    HCPCS E0492eXciteOSA
    HCPCS E0493eXciteOSA
    HCPCS E0530Electronic positional obstructive sleep apnea treatment with sensor
    Cited LCDs and LCAsmixed
    L38276LCD - Hypoglossal Nerve Stimulation for Obstructive Sleep Apnea
    L33718LCD - Positive Airway Pressure (PAP) Devices for the Treatment of Obstructive Sleep Apnea
    L33800LCD - Respiratory Assist Devices
    L35050LCD - Outpatient Sleep Studies
    A52512LCA - Oral Appliances for Obstructive Sleep Apnea
    L38398First Coast Service Options LCD - Hypoglossal Nerve Stimulation
    L38387National Government Solutions LCD - Hypoglossal Nerve Stimulation
    L38310Noridian LCD - Hypoglossal Nerve Stimulation
    L38385Novitas Solutions LCD - Hypoglossal Nerve Stimulation
    Coding resources referencedmixed
    Sleep Medicine CodesReference to AASM Sleep Medicine Codes resource (no explicit CPT/HCPCS codes listed in these chunks)
    inv-118: AHI/REI/AHI thresholds — summary key thresholds
    Primary OSA thresholdAHI/RDI on PSG or AHI/REI on HSAT ≥15 events/hour
    Mild OSA threshold with symptoms/comorbidityAHI/REI ≥5 and <15 events/hour with documented symptoms (sleepiness, awakenings with gasping) or listed comorbidities (hypertension, CHF, AF, CAD, T2DM, stroke, mood/cognitive disorders)
    Scoring basisAHI = apneas + hypopneas per hour of sleep (PSG) or estimated sleep (HSAT/REI)
    inv-119: Diagnostic indices and physiologic thresholds
    OSA diagnostic indicesAHI/RDI (PSG) or AHI/REI (HSAT) ≥15 events/hr; or 5–14.9 events/hr with qualifying symptoms/comorbidities
    Central sleep apnea indexCentral apnea and/or central hypopnea index ≥5 events/hour AND central events >50% of total apneas/hypopneas
    Sleep-related hypoventilationSleep PCO2 (arterial/EtPCO2/TcPCO2) >55 mmHg for ≥10 minutes OR ≥10 mmHg rise to >50 mmHg for ≥10 minutes
    inv-120: OHS PaCO2 / serum bicarbonate thresholds
    OHS diagnostic PaCO2 threshold (awake)Awake ABG, EtPCO2, or TcPCO2 PCO2 ≥45 mmHg
    OHS venous blood gas thresholdVBG PCO2 ≥50 mmHg
    Serum bicarbonate noteSerum bicarbonate ≥27 mmol/L has high negative predictive value to exclude hypercapnia; <27 effectively rules out hypercapnia in low–moderate pretest probability
    inv-121: HSAT REI/AHI scoring
    HSAT REI/AHI calculationAHI (REI on HSAT) = number of apneas + hypopneas per hour of estimated sleep
    RDI limitation on HSATRDI (includes RERAs) cannot be scored on HSAT because RERAs are not detectable with HSAT
    PSG scoring basisOn PSG, AHI = apneas + hypopneas per hour of sleep; RDI includes RERAs per hour of sleep
    inv-122: Physiologic thresholds (BMI, PaCO2, desaturation)
    BMI thresholds repeatedly usedBMI ≥30 kg/m2 used across multiple indications; BMI ≥45 cited as threshold prompting in-lab PSG
    Severe COPD PaCO2 thresholdArterial blood gas PaCO2 ≥52 mmHg for severe COPD indication
    Sustained desaturation thresholdSustained oxygen desaturation ≤88% lasting ≥5 total minutes (independent of respiratory events)
    inv-123: Split night AHI threshold
    Split-night diagnostic AHI thresholdAHI ≥15 events/hour during at least 2 hours of diagnostic PSG recording
    Minimum titration timeAt least 3 hours must be available for PAP titration during the same night
    Split-night appropriatenessSplit-night study used when above criteria are met per AASM guidance
    inv-124: PAP efficacy/adherence threshold
    PAP efficacy definitionTherapy download shows AHI <5 events/hour (on PAP) — required for considering MSLT/MWT and some procedural prerequisites
    PAP adherence definitionUse ≥4 hours/night on 70% of nights during a consecutive 30‑day period (documentation within prior 6 months may be required)
    Compliance window30 continuous days of compliance data within 6 months prior to request for many supply/device approvals
    inv-125: Clinical thresholds referenced (examples)
    Common clinical thresholds — PAP adherence≥4 hours/night on 70% of nights over a consecutive 30‑day period (used for continuation, replacement, supplies)
    Weight-change trigger for retesting≥10% weight change (gain or loss) used to prompt repeat diagnostic or titration testing
    HGNS pre-implant numeric limitsBMI ≤40 and AHI/REI ≤100 in pre-implant evaluation criteria
    inv-126: Central apnea index / AHI thresholds
    Common central apnea thresholds for device candidacyCentral AHI ≥15 events/hour frequently used to define moderate–severe CSA for intervention
    Pivotal trial entry criteria (example)Pivotal trial used higher thresholds (e.g., AHI ≥20 with central AI ≥50% and ≥30 central events) for some TPNS/Invasive device studies
    Device study contextDevice-specific pivotal/reST studies used variable higher numeric cutoffs for enrollment versus operational guidance thresholds
    inv-127: BMI threshold used repeatedly
    BMI eligibility threshold (repeated)BMI ≥30 kg/m2 used as an eligibility threshold for many pre-treatment and repeat testing indications
    Higher BMI prompting PSGBMI ≥45 cited as a specific criterion prompting in‑lab PSG rather than HSAT
    Weight-change guidanceSignificant weight change (≥10%) influences repeat testing and device candidacy
    inv-128: Age for pediatric PSG
    Pediatric PSG age cutoffChildren 17 years of age or younger (≤17 years) for pediatric in‑lab full‑night diagnostic PSG indications
    Pediatric severity cutoffsPediatric OSA severity: Mild 1 to <5, Moderate ≥5 to <10, Severe ≥10 events/hour
    Pediatric PSG coding noteUse CPT 95782/95783 for pediatric in‑lab diagnostic and PAP titration studies as specified
    inv-129: OSA AHI/REI thresholds (restated)
    Restated OSA thresholdsOSA defined as AHI/RDI (PSG) or AHI/REI (HSAT) ≥15 events/hour OR 5–14.9 events/hour with qualifying symptoms or comorbidities
    Symptom/comorbidity examplesSymptoms: sleepiness, gasping/arousals; Comorbidities: HTN, CHF, AF, CAD, T2DM, stroke, mood/cognitive disorders
    Test types specifiedValid testing includes in‑lab PSG (AHI/RDI) or HSAT (AHI/REI)
    inv-130: Central apnea index (restated)
    Central apnea index restatedCentral apnea and/or central hypopnea index ≥5 per hour AND central events >50% of total apneas/hypopneas
    Symptom requirementPresence of one or more symptoms (sleepiness, witnessed apneas, awakenings short of breath) required in CSA definition
    Cheyne‑Stokes noteCSA with Cheyne‑Stokes requires crescendo–decrescendo cycles and additional cardiac/neurologic context
    inv-131: Hypoventilation PCO2 thresholds
    Hypoventilation PCO2 absolute thresholdIncrease in arterial/transcutaneous/end‑tidal PCO2 to >55 mmHg for ≥10 minutes during sleep
    Relative PCO2 rise criterionOr a ≥10 mmHg rise from awake supine to a value >50 mmHg for ≥10 minutes during sleep
    Measurement methodsMeasured via arterial blood gas (PaCO2), transcutaneous (TcPCO2), or end‑tidal (EtPCO2)
    inv-132: AHI/RDI/REI threshold >=5 events/hr
    Minimum AHI/RDI/REI to define sleep apnea events≥5 events per hour used as minimum threshold in multiple contexts (eg. treatment‑emergent CSA definition, oral appliance eligibility with symptoms)
    Scoring basis reminderAHI = apneas + hypopneas per hour (PSG) or estimated sleep (HSAT/REI). RDI includes RERAs (PSG only).
    Clinical useAHI ≥5 often used to trigger further evaluation when accompanied by symptoms or other criteria
    inv-133: PCO2 thresholds for hypoventilation
    Primary PCO2 thresholds for hypoventilation>55 mmHg for ≥10 minutes OR increase ≥10 mmHg to a value >50 mmHg for ≥10 minutes (during sleep)
    Awake PaCO2 threshold for OHS/other hypoventilationAwake PaCO2, EtPCO2, or TcPCO2 ≥45 mmHg used to define awake hypercapnia for OHS and other indications
    VBG thresholdVenous blood gas PCO2 ≥50 mmHg is an accepted alternative for hypoventilation/ OHS confirmation
    inv-134: Arterial blood gas thresholds
    Arterial blood gas (PaCO2) thresholdsPaCO2 ≥45 mmHg (neuromuscular/restrictive indications) or PaCO2 ≥52 mmHg (severe COPD indication)
    VBG/EtPCO2/TcPCO2 equivalenceEtPCO2/TcPCO2 ≥45 mmHg or VBG PCO2 ≥50 mmHg used as alternative measures depending on clinical context
    Documentation requirementObjective physiologic data (ABG/PaCO2, EtPCO2/TcPCO2, VBG) required for advanced PAP device initiation (E0470/E0471) indications
    inv-136: Usage compliance — PAP usage definition
    PAP usage compliance definitionDevice used ≥4 hours per night on 70% of nights during a consecutive 30‑day period (documented anytime during the first 3 months or within prior 6 months depending on context)
    Clinical reevaluation timingClinical reevaluation required within the first 3 months after PAP initiation to assess symptoms and response
    Supply/device requestsMany supplies and replacement device approvals require 30 continuous days of compliance data within 6 months prior to request
    inv-137: PAP compliance operational definition
    Operational PAP compliance for approvalsDevice download showing ≥4 hours/night on 70% of nights with 30 continuous days of data within the prior 6 months is required for many supply/device approvals
    Compliance data window30 continuous days of compliance data must be within 6 months before the date of request for masks, tubing, accessories
    Frequency linkageCoverage frequencies (eg 1 per 3 months for masks/tubing) are contingent on meeting compliance criteria
    inv-138: OSA diagnostic thresholds for oral appliance
    Oral appliance diagnostic thresholdAHI, RDI, or REI ≥5 events/hour with clinical symptoms/comorbidities OR ≥15 events/hour to qualify for custom-fit oral appliance therapy
    PAP trial requirementDocumentation of intolerance or lack of benefit after a minimum one‑month trial of PAP is required unless PAP is contraindicated or patient preference with AHI <30
    Provider/dentist requirementsDevice ordered by treating medical provider after face‑to‑face visit; custom device provided and followed by a qualified licensed dentist
    inv-139: Night-to-night variability note (references)
    Night‑to‑night variability noteReferences note AHI variability and potential need for multi‑night testing or repeat assessment due to variability and misclassification risk
    Selected referencesCited studies: Short‑term variability in AHI (Prasad et al. 2016); variability and misclassification (Punjabi et al. 2020)
    Clinical implicationConsider repeat or multi‑night testing when results are borderline or when clinical picture and single‑night result conflict

    Provider Actions — Ordering, Documentation, and Authorization

    Prior Authorization

    Order by treating provider; interpretation by board‑certified sleep medicine physician

    HSAT and/or PSG orders must be placed by a treating medical provider and interpretation must be by a board‑certified sleep medicine physician or a provider overseen by one. A reasonable attempt to obtain prior sleep testing results must be documented before requesting repeat testing.

    • Treating medical provider = MD, DO, NP, Clinical Nurse Specialist, or PA
    • Document attempts to obtain prior study (contact prior facility/provider or DME; ask patient for copy)
    Prior Authorization

    In‑lab full‑night PAP titration required when bilevel PAP is requested for listed indications

    An in‑lab full‑night PAP titration is medically necessary when bilevel PAP (HCPCS E0470 or E0471) is specifically requested for listed conditions — e.g., after unsuccessful APAP/CPAP trial or for diagnoses such as central sleep apnea, treatment‑emergent CSA, neuromuscular/restrictive thoracic disease, severe COPD (PaCO2 ≥52 mmHg), obesity hypoventilation syndrome, or other hypoventilation disorders.

    • Bilevel requested because CPAP/APAP ineffective or not tolerated
    • Objective physiologic thresholds (e.g., PaCO2 ≥52 mmHg for severe COPD; OHS PCO2 criteria) apply
    Note

    Inclusion of codes does not imply PA or management requirement

    The presence of a code in the guideline coding tables does not in itself mean that the code is managed or requires prior authorization; refer to the applicable health plan for plan‑specific management and prior authorization details.

    • Prior authorization of a listed code is not a guarantee of payment
    • Check the member's Certificate of Coverage / Evidence of Coverage for plan specifics
    Prior Authorization

    Prior authorization expected for in‑lab PSG (including pediatrics) when indications present

    Prior authorization is expected when in‑lab polysomnography (full‑night, split‑night, or in‑lab PAP titration) is requested because clinical evaluation indicates sleep‑disordered breathing and one or more listed indications or comorbid conditions are documented; pediatric in‑lab PSG uses CPT 95782/95783.

    • Document at least one PSG indication or comorbidity per guideline (e.g., BMI thresholds, pulmonary/cardiac/neurologic conditions)
    • Use CPT 95782/95783 for pediatric in‑lab PSG/titration
    Prior Authorization

    Authorization conditions for split‑night PSG and PSG+MSLT

    Split‑night PSG is appropriate only when diagnostic AHI ≥15/hour during ≥2 hours of diagnostic recording and at least 3 hours remain available for PAP titration; PSG immediately followed by MSLT must meet documented MSLT prerequisites and follow an attended PSG on adequate sleep/treatment settings.

    • Split‑night: AHI ≥15/hr during ≥2 hours and ≥3 hours available for titration
    • MSLT: must immediately follow an attended PSG and meet duration/sleep sufficiency and exclusion criteria
    Prior Authorization

    Prior authorization may be required for HGNS‑related pre‑ and post‑implant PSGs

    Pre‑implant and post‑implant in‑lab PSGs for hypoglossal nerve stimulator evaluation and device optimization are medically necessary under the guideline's specified criteria and may require prior authorization when requested for HGNS evaluation or fine‑tuning.

    • Pre‑implant: HSAT and PAP trial recommended if no prior testing; in‑lab pre‑implant PSG required when pre‑specified criteria (BMI ≤40, AHI/REI ≤100, PAP intolerance after 3‑month trial, etc.) are met
    • Post‑implant: in‑lab PSG ≥2 months post‑implant for parameter fine‑tuning; repeat PSG if clinical response insufficient or prior test inadequate
    Prior Authorization

    Prior authorization for TPNS‑related PSGs (pre‑ and post‑implant)

    Polysomnography is medically necessary prior to TPNS implantation when all listed pre‑implant eligibility criteria are met (e.g., age ≥18, central AHI ≥15/hr, CSA not primarily opioid‑related, absence of transient causes, and documentation of prior PAP contraindication/failure/intolerance after a ≥3‑month trial); such PSGs and post‑implant programming PSGs may require prior authorization.

    • Pre‑implant: document central AHI ≥15/hr and prior ≥3‑month PAP trial failure/intolerance
    • Post‑implant: PSG with device interrogation/programming can be performed ≥2 months after implantation for optimization
    Prior Authorization

    PSG for TPNS evaluation and post‑implant programming

    Polysomnography with phrenic nerve stimulator interrogation/programming may be performed at least 2 months post‑implant for device optimization; repeat in‑lab PSG is medically necessary if clinical response is insufficient or prior test was inadequate.

    • Initial post‑implant PSG timing: ≥2 months after implantation
    • Retest triggers: insufficient clinical response or inadequate prior test (report required)
    Denial Risk

    Do not rely on repeat sleep testing solely to continue/resume Zepbound

    A repeat sleep study should not be ordered solely to continue or resume Zepbound (tirzepatide); prior authorization/justification must not rely on repeat testing alone and reassessment should follow the guideline's repeat‑testing rules.

    • For Zepbound continuation/resumption, do not use repeat diagnostic testing as the sole justification
    • Follow SL‑2.6 Repeat sleep testing guidance for reassessment while on or after Zepbound
    Note

    PAP device and supply codes listed — inclusion does not imply PA

    Treatment device and supply HCPCS/CPT codes (PAP devices, interfaces, humidifiers, monitoring, and related supplies) are listed in the guideline; inclusion of these codes does not itself indicate a prior authorization requirement — check the member's plan.

    • Examples include E0601, E0470, E0471, E0472, E0561, E0562, A7027–A7046, A9279, and CPT 94660
    • Refer to the health plan for plan‑specific prior authorization rules
    Prior Authorization

    Prior authorization required for E0601 and E0470/E0471 device initiation/purchase

    Prior authorization is required for initiation/purchase of HCPCS E0601 (APAP/CPAP) and HCPCS E0470/E0471 (Bi‑level PAP) devices; orders must follow a documented clinical evaluation and be based on qualified testing.

    • E0601 initiation requires positive diagnosis (HSAT or PSG) and order by treating provider after clinical evaluation
    • Authorization for purchase requires documentation of compliance/reevaluation and plan‑specific requirements
    Prior Authorization

    PA for PAP/ASV requires documented qualifying condition and objective testing

    Prior authorization for PAP devices including ASV (E0471) requires documentation of one of the qualifying medical conditions and supporting objective testing/results as specified in the guideline (e.g., CSA criteria, neuromuscular disease with physiologic data, severe COPD with PaCO2 thresholds).

    • Document the qualifying diagnosis (central sleep apnea, treatment‑emergent CSA, neuromuscular disease, severe COPD, OHS, or other hypoventilation)
    • Include objective physiologic data (ABG/PaCO2, EtPCO2/TcPCO2, vital capacity, nocturnal oximetry) as required
    Note

    Inclusion of a code does not by itself indicate PA is required

    Again, inclusion of a code in the guideline's coding tables does not by itself mean prior authorization is required; verify plan‑specific management and prior authorization requirements with the applicable health plan.

    • Prior authorization determinations depend on the member's benefit plan
    • Listing a code in the document does not guarantee coverage or payment
    Billing Rule

    CPT 94799 / HCPCS E1399 not approvable for routine PAP equipment/supplies

    Use of nonspecific DME codes (CPT 94799 or HCPCS E1399) for routine PAP machines, parts, or supplies is generally not approvable; E1399 may be approved only for specific items (e.g., PAP oxygen bleed‑in adapter) or specified repair parts when the DME supplier documents needed replacements.

    • Do not submit CPT 94799 or E1399 for routine PAP equipment/supplies when specific HCPCS codes exist
    • E1399 may be approved for limited items or repair parts with supplier justification
    Note

    Multiple CMS LCDs/LCA identifiers cited — confirm LCD‑based coverage rules

    The policy cites multiple CMS Local Coverage Determinations and LCA identifiers (e.g., L38276, L33718, L33800, L35050) — device and sleep‑study related services may be subject to LCD‑based coverage or prior authorization rules; confirm applicable LCD requirements.

    • Check cited LCDs (Hypoglossal Nerve Stimulation, Respiratory Assist Devices, Outpatient Sleep Studies, etc.) for coverage specifics
    • Noncompliance with an applicable LCD may affect coverage
    Documentation Required

    Attach relevant FDA PMA/SSED or manufacturer documents for device prior authorizations

    FDA PMA and SSED documents for implantable devices (Inspire UAS, Genio® System 2.1, aura6000®, remede®) are cited as supporting regulatory evidence; attach relevant PMA/SSED documents when submitting device‑related prior authorization requests as appropriate.

    • Attach manufacturer or FDA PMA/SSED documents for HGNS/TPNS/other implantable device requests when relevant
    • Manufacturer manuals and billing guides are also cited as supporting documentation
    Note
    Step Therapy

    Documented APAP trial (≥30 days) required before in‑lab titration for unsuccessful APAP

    Documented APAP (auto‑PAP) trial of at least 30 days is required before in‑lab PAP titration when OSA persists; acceptable failure evidence includes APAP download showing AHI ≥5/hr with ongoing symptoms, APAP use ≥4 hours/night on 70% of nights with continued symptoms, or APAP intolerance despite interventions.

    • APAP trial duration: ≥30 days
    • Acceptable failure criteria: AHI ≥5/hr on machine download with symptoms OR adherence ≥4 hrs/night on 70% nights with persistent symptoms OR documented intolerance despite DME/provider interventions
    Documentation Required

    Acceptable documentation for APAP trial failure

    APAP therapy trial documentation must include at least a 30‑day trial and one of: APAP machine download with AHI ≥5/hr plus ongoing OSA symptoms; APAP usage ≥4 hours/night on 70% of nights with persistent symptoms; or documented APAP intolerance despite mask fittings, alternative masks, pressure adjustments, or desensitization.

    • Upload APAP machine download and symptom documentation when claiming APAP failure
    • Document interventions attempted to address intolerance (mask refitting, education, pressure changes)
    Step Therapy

    In‑lab titration indicated when APAP trial (≥30 days) fails per defined metrics

    A titration study is medically necessary if an APAP trial of at least 30 days has failed per the guideline metrics (machine download AHI ≥5 with symptoms; or APAP use ≥4 hours/night on 70% of nights with persistent symptoms) or if APAP intolerance persists despite interventions.

    • Confirm APAP trial length and provide machine download or adherence data
    • If split‑night was attempted but not completed, follow guidance on whether a second‑night titration or at‑home APAP treatment is appropriate
    Note

    When split‑night not completed, choose second‑night titration vs immediate at‑home APAP per guidelines

    If a split‑night study cannot be completed, the next step is either a second‑night in‑lab full‑night PAP titration or initiation of immediate at‑home APAP (E0601) per the general guidelines; decision depends on indications, comorbidities, and prior testing.

    • Consider patient comorbidities and prior test adequacy when choosing second‑night titration versus immediate at‑home APAP
    • Follow At‑home vs In‑lab testing guidance (SL‑1.0) for selection
    Step Therapy

    HSAT and PAP trial recommended before facility HGNS testing

    For HGNS evaluation, individuals without prior testing should undergo HSAT (if appropriate) and a PAP trial before consideration of in‑lab testing for implantation; evaluations should be performed by or in consultation with a board‑eligible/certified sleep medicine physician.

    • If no prior testing, perform HSAT and PAP trial before facility testing for HGNS candidacy
    • Document specialist involvement (board‑eligible/certified sleep physician) for pre‑implant evaluation
    Step Therapy

    Document ≥3‑month PAP trial (or contraindication) before TPNS consideration

    Documentation for TPNS pre‑implantation must show prior PAP contraindication, failure, or intolerance after a minimum three‑month trial (mask fittings, alternative masks, pressure changes, desensitization documented); oxygen must be contraindicated/ineffective or not tolerated.

    • Minimum PAP trial: 3 months with documented interventions
    • Document supplemental oxygen contraindication/ineffectiveness or intolerance when claimed
    Step Therapy

    Recommend comprehensive lifestyle weight‑loss therapy before pharmacotherapy

    Patients with overweight or obesity should first receive comprehensive lifestyle intervention (diet, exercise, behavioral counseling) before considering anti‑obesity pharmacotherapy, consistent with ATS/AACE/ACE recommendations referenced in the guideline.

    • Lifestyle intervention goal: weight‑loss program before pharmacotherapy evaluation
    • Anti‑obesity pharmacotherapy considered when lifestyle measures insufficient per guideline recommendations
    Prior Authorization

    CPAP medically necessary in children after PSG‑confirmed OSA if surgery unsuccessful or inappropriate

    In pediatrics, CPAP is medically necessary when obstructive sleep apnea is established by PSG and adenotonsillectomy was unsuccessful or is inappropriate, or definitive surgery must await dental/facial development.

    • PSG‑documented OSA required
    • Document adenotonsillectomy failure or inappropriateness when claiming CPAP
    Step Therapy

    Trial of CPAP/APAP required and proven ineffective before Bi‑level PAP for OSA

    For OSA, CPAP/APAP (E0601) should be tried and proven ineffective or not tolerated before initiating Bi‑level PAP (E0470) for OSA indications; document the trial and interventions attempted.

    • Document CPAP/APAP trial and reasons for failure (pressure discomfort, intolerance) before requesting bilevel for OSA
    • Include evidence of attempted optimization (mask refitting, education, pressure adjustments)
    Step Therapy

    Consider ASV only after CPAP proven ineffective for specified central apnea indications

    ASV may be considered after CPAP has been shown ineffective for certain central apnea indications; prior CPAP/APAP/bi‑level attempts and relevant objective testing must be documented as specified in ASV guidance.

    • Document prior mask‑based therapy attempts and objective testing meeting CSA criteria
    • Discuss benefits/risks and plan for follow‑up when ordering ASV in HFrEF
    Step Therapy

    Oral appliance requires documented 1‑month PAP trial (unless contraindicated) or documented intolerance

    Coverage of a custom oral appliance requires documentation of intolerance or lack of benefit after a minimum one‑month trial of PAP unless PAP is contraindicated or the patient prefers an alternative; appliance orders must follow a face‑to‑face visit and review of sleep study results.

    • One‑month PAP trial required (documented) unless contraindicated
    • Order must be placed by treating medical provider after face‑to‑face visit; qualified dentist provides custom device
    Note
    Note
    Note

    No additional step‑therapy requirements specified in reference sections

    No additional step‑therapy requirements are specified in the referenced sections of the guideline beyond the therapy trials and sequencing already detailed (APAP before titration, CPAP before bilevel for OSA, PAP trials before implantable therapies, etc.).

    • Follow the guideline's specific step‑therapy rules for APAP, CPAP, and device‑related therapies
    • Check plan‑specific policies for any additional step‑therapy requirements
    Documentation Required

    Comprehensive clinical evaluation required before sleep testing

    A current comprehensive clinical evaluation (face‑to‑face or telehealth) including sleep symptoms, physical exam (cardiopulmonary exam, obesity, neck circumference, oropharyngeal exam) and relevant diagnostics/labs (ABG or serum bicarbonate within one year) is required prior to testing.

    • Include comprehensive sleep history, physical exam, and relevant prior diagnostics in documentation
    • ABG or serum bicarbonate within one year when applicable
    Documentation Required

    Include clinical evaluation and prior test reports when available

    Clinical documentation submitted with testing or device requests must include the evaluation supporting concern for OSA or other sleep‑disordered breathing, and prior HSAT/PSG reports when relevant (to demonstrate non‑diagnostic or technically inadequate studies).

    • Attach prior HSAT/PSG reports when claiming prior non‑diagnostic or technically inadequate testing
    • Document signs/symptoms and relevant comorbidities to justify in‑lab testing when indicated
    Documentation Required

    Provide full clinical description when requesting titration or parasomnia diagnostics

    When requesting titration or certain diagnostics (e.g., complicated parasomnias), include a complete description, assessment, and discussion of signs and symptomatology to support medical necessity.

    • For parasomnias, describe dream‑enacting behaviors, injury risk, or concern for nocturnal seizures
    • Provide narrative assessment linking symptoms to the requested in‑lab study
    Documentation Required

    HSAT device must meet minimum technical features (FDA clearance, oximetry, raw data, REI calculation)

    HSAT devices must meet minimum technical features — FDA approval/clearance for SDB diagnosis, unique unit identifier, capability to record oximetry and heart rate, raw data display for review, and ability to calculate an REI (or estimated sleep time for PAT devices).

    • Document device model/unique identifier and FDA clearance when submitting HSAT‑based testing
    • Ensure raw data are available for manual scoring or review
    Documentation Required

    Use CPT 95782/95783 for pediatric PSG and submit supporting prior test/APAP data

    For pediatric in‑lab PSG requests, use CPT 95782/95783 as appropriate and include prior HSAT/PSG reports when applicable to demonstrate prior non‑diagnostic HSAT or unsuccessful APAP trials.

    • 95782 = pediatric full‑night diagnostic PSG; 95783 = pediatric in‑lab PAP titration
    • Attach prior testing reports and APAP download/adherence data when relevant
    Documentation Required

    Provide detailed clinical description for parasomnias or suspected RBD

    When requesting in‑lab PSG for complicated parasomnias or suspected REM behavior disorder, provide a complete description, assessment, and discussion of the dream‑enacting or injurious behaviors and any concern for nocturnal seizures.

    • Describe specific behaviors, timing, severity, and safety concerns
    • Note whether standard EEG was inconclusive when differentiating seizure vs parasomnia
    Documentation Required

    Document 3+ months of daytime sleepiness and sufficient sleep before PSG+MSLT

    For MSLT requests, document recurrent daytime naps or lapses into sleep for at least 3 months, associated symptoms (e.g., cataplexy), exclusion of other causes of sleepiness, and demonstration of sufficient prior sleep; MSLT must immediately follow an attended PSG.

    • Duration requirement: ≥3 months of recurrent daytime sleepiness
    • Confirm sufficient sleep prior to PSG per age‑based hours; MSLT follows PSG directly
    Documentation Required

    Submit prior sleep study reports and PAP device download data when relevant

    When relevant, submit prior medically necessary sleep test reports and PAP device download data (adherence, AHI on device) to support requests for repeat testing, titration, replacement, or device upgrades.

    • Include PAP download showing usage and AHI when claiming APAP/CPAP failure or requesting replacement
    • Document efforts to obtain prior reports if original report unavailable
    Documentation Required

    HGNS evaluation must involve board‑eligible/certified sleep medicine physician

    HGNS pre‑implant evaluations should be performed by or in consultation with a board‑eligible or board‑certified sleep medicine physician; document specialist involvement in the submission.

    • Note the evaluating clinician's certification status and any consultative involvement
    • Attach evaluation notes that document PAP trial history and candidacy criteria
    Documentation Required

    Prior sleep study report required to justify repeat testing

    When prior sleep testing exists and repeat testing is requested, include the prior sleep study report to determine medical necessity; document symptom, weight, medication, neurologic, or cardiovascular changes when using those as justification for repeat testing.

    • Prior report required to justify repeat HSAT or PSG
    • Document specific clinical changes (≥10% weight change, new/worsening symptoms, med changes) supporting repeat testing
    Documentation Required

    TPNS evaluation requires sleep medicine specialist involvement and detailed prior study/PAP documentation

    TPNS evaluation must be performed by a board‑eligible/certified sleep medicine physician or in consultation with one; documentation must include prior CSA diagnosis details (date, central AHI) and prior PAP trial information.

    • Include prior study central AHI and dates
    • Document prior PAP trial duration, intolerance/failure, and oxygen contraindication if applicable
    Documentation Required

    Pediatric PSG requests must document age, symptoms, and at least one objective finding

    For pediatric in‑lab PSG requests, document the child's age (≤17 years), presenting symptoms/signs (e.g., snoring, witnessed apnea, daytime sleepiness), and at least one objective related finding (e.g., tonsillar hypertrophy, failure to thrive) linking concern to OSA; provide reasons for split‑night testing if requested.

    • Age documentation (≤17) required
    • List specific presenting symptoms and objective findings linking to OSA
    Documentation Required

    Documentation must support listed symptoms or clinical circumstances for testing/titration

    Documentation submitted for any testing, titration, or device request must support one or more listed symptoms or specific clinical circumstances in the guideline (e.g., snoring, witnessed apnea, growth impairment, Down syndrome screening).

    • Cite the guideline‑listed symptom(s) or circumstance(s) that justify the requested service
    • For split‑night in pediatrics, provide reason(s) for split‑night approach
    Note
    Note
    Note
    Documentation Required

    DME evaluation required and warranty status documented for replacement claims

    For replacement device claims, include documentation that the DME supplier physically evaluated the device and determined it cannot be repaired; failure to provide DME evaluation or if the device remains under warranty risks denial.

    • DME supplier physical evaluation report required
    • Confirm device is no longer covered under warranty
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Note
    Billing Rule

    PAP devices and supplies must be ordered by a treating medical provider

    Orders for PAP devices and supplies can only be placed by a treating medical provider (licensed MD, DO, NP, Clinical Nurse Specialist, or PA); ensure the order originates from an eligible provider.

    • Non‑prescribers or administrative staff cannot place orders independently
    • Include treating provider credentials on the order
    Documentation Required

    Document PAP usage ≥4 hrs/night on 70% nights over 30 days and clinical reevaluation

    To establish PAP usage and eligibility for continuation or replacement, document device usage of ≥4 hours per night on 70% of nights during a consecutive 30‑day period; failure to document this adherence or lack of a clinical reevaluation within 3 months may result in denial.

    • Compliance metric: ≥4 hrs/night on 70% of nights over 30 consecutive days
    • Clinical reevaluation within first 3 months required for continued coverage
    Note
    Denial Risk

    Replacement denied if device under warranty or not evaluated by DME

    Replacement requests may be denied if the device remains under warranty or the DME supplier has not determined it cannot be repaired; include warranty documentation and DME repair evaluation to avoid denial.

    • Provide copy of warranty status and DME repair assessment
    • If device repairable, replacement request may be denied
    Note
    Note
    Note
    Note

    Definitions and Diagnostic Thresholds

    inv-211: Obstructive sleep apnea (OSA) definition and thresholds
    OSA definitionObstructive sleep apnea defined by AHI/RDI (PSG) or AHI/REI (HSAT) ≥15 events/hr, or 5–14.9 events/hr with qualifying symptoms or comorbidities
    Scoring basisAHI = apneas + hypopneas per hour of sleep (PSG) or estimated sleep (HSAT/REI); RDI includes RERAs on PSG
    Diagnostic modalitiesValid testing includes in‑lab PSG (preferred for complex comorbidity) or HSAT for uncomplicated adults per guidelines
    inv-212: Central sleep apnea (CSA) definition
    CSA definitionCentral sleep apnea defined by one or more symptoms (sleepiness, witnessed apneas, awakenings short of breath) AND central apnea/hypopnea index ≥5/hr with central events >50% of total
    Associated conditionsCSA with Cheyne‑Stokes requires known AF/flutter, CHF, or neurologic disorder and crescendo–decrescendo breathing cycles ≥40 seconds
    Treatment‑emergent CSADefined when obstructive events resolve on PAP but central index ≥5/hr and central events >50% of total on PSG during PAP without backup rate
    inv-213: OSA definition (restated)
    OSA restatedAHI/RDI ≥15 OR 5–14.9 with symptoms/comorbidities (same thresholds reiterated)
    Symptoms examplesSleepiness, gasping/arousals, habitual snoring, impaired quality of life
    Testing typesPSG (AHI/RDI) or HSAT (AHI/REI) as valid tests
    inv-214: CSA definition (restated)
    CSA restatedPresence of symptoms plus central index ≥5/hr and central events >50% of total apneas/hypopneas
    Clinical signsSleepiness, awakening short of breath, witnessed apneas
    ImplicationMeets criteria for advanced therapies and specific device consideration (ASV/TPNS) per guidance
    inv-215: CSA with Cheyne-Stokes Breathing
    CSA with Cheyne‑Stokes BreathingMeets CSA criteria plus AF/flutter, CHF, or neurologic disorder AND breathing pattern with ≥3 consecutive central events in crescendo–decrescendo cycles with cycle length ≥40 seconds
    Pattern requirement≥3 consecutive central apneas/hypopneas with crescendo‑decrescendo amplitude and cycle length ≥40 sec
    Clinical contextOften associated with heart failure or neurologic disease; relevant for ASV/TPNS consideration
    inv-216: Treatment-emergent central sleep apnea
    Treatment‑emergent CSAPredominantly obstructive AHI/RDI or AHI/REI ≥5 with PSG during PAP showing resolution of obstructive events but central index ≥5/hr and central events >50% of total
    PAP study requirementPSG during PAP without backup rate must show significant resolution of obstructive events with central predominance
    Clinical relevanceMay trigger consideration of ASV or other advanced therapies per guidelines
    inv-217: Sleep-related hypoventilation
    Sleep‑related hypoventilation definitionEither sleep PCO2 (arterial, transcutaneous, or end‑tidal) >55 mmHg for ≥10 minutes OR a ≥10 mmHg increase from awake supine to >50 mmHg for ≥10 minutes
    Measurement modalitiesArterial PaCO2, EtPCO2, or TcPCO2 recommended measures; VBG may be used in some contexts
    Clinical implicationUsed to identify candidates for advanced PAP or ventilatory support therapies
    inv-218: Obesity hypoventilation syndrome (OHS)
    Obesity hypoventilation syndrome (OHS)BMI ≥30 kg/m2 PLUS either awake ABG/EtPCO2/TcPCO2 PCO2 ≥45 mmHg OR VBG PCO2 ≥50 mmHg
    Serum bicarbonate utilitySerum bicarbonate ≥27 mmol/L has high NPV to exclude hypercapnia; <27 effectively rules out hypercapnia in low–moderate pretest probability
    Additional clinical criteriaDiagnosis considers clinical context (recent hospitalization with persistent hypoventilation, ongoing hypoventilation despite CPAP), per device initiation rules
    inv-219: AHI and RDI definitions
    AHI definitionAHI = number of apneas + hypopneas per hour of sleep (PSG) or per hour of estimated sleep (HSAT/REI)
    RDI definitionRDI = apneas + hypopneas + RERAs per hour of sleep (PSG only) — RDI cannot be scored on HSAT
    REI termREI often used interchangeably with AHI on HSAT devices that estimate sleep time
    inv-220: PLMD vs RLS definitions
    PLMD vs RLSPLMD: periodic limb movements during sleep associated with insomnia or daytime impairment (requires PSG); RLS: clinical diagnosis of evening/worsening leg sensations relieved by movement — does not require PSG
    PLMD testing caveatPLMS on sleep testing does not equate to PLMD; PLMD is rare and diagnosis requires clinical correlation
    HSAT roleHSAT should be used to evaluate OSA before diagnosing PLMD in absence of comorbidities per guidance
    inv-221: Pediatric Polysomnography (CPT 95782/95783) description
    Pediatric PSG CPT codesCPT 95782 (diagnostic in‑lab full night for children <6 with 4+ additional parameters) and 95783 (PAP titration for children <6)
    Attended study requirementPediatric PSG is attended by a technologist with age‑appropriate monitoring parameters
    Use and reportingReport CPT 95782 or 95783 as appropriate and include prior HSAT/PSG reports when applicable
    inv-222: Sleep-related hypoxemia definition
    Sleep‑related hypoxemia thresholdSustained oxygen saturation ≤88% lasting at least 5 total minutes in absence of apneas/hypopneas on prior study
    Alternate saturation metricOxygen saturation ≤90% for ≥5% of the night also referenced for some device/therapy criteria
    Clinical relevanceSustained hypoxemia may prompt in‑lab evaluation and consideration of ventilatory support therapies
    inv-223: Suspected PLMD
    Suspected PLMD definitionPeriodic repetitive limb movements during sleep associated with insomnia or impaired daytime functioning not caused by other sleep, medical, or mental disorders
    Diagnostic requirementPLMD suspicion warrants PSG if movements are associated with insomnia/daytime impairment and other causes (untreated OSA, RLS, narcolepsy, RBD) excluded
    RLS distinctionRLS is a clinical diagnosis and does not require PSG
    inv-224: REM Behavior Disorder (RBD) definition
    REM Behavior Disorder (RBD)Acting out vivid, intense dreams with sleep‑related vocalizations and complex motor behaviors correlating with dream‑enacting mentation; requires clear description for PSG consideration
    Diagnostic cueDream‑enacting behaviors such as punching or jumping from bed with vocalization prompt in‑lab PSG evaluation
    DifferentialRBD should be distinguished from other parasomnias and seizure disorders; PSG may be required for diagnosis
    inv-225: Pediatric hypopnea scoring
    Pediatric hypopnea scoringApnea: ≥90% drop in peak signal excursion for ≥2 breaths (oronasal thermal sensor); Hypopnea: >30% drop using nasal pressure for ≥2 breaths with ≥3% desaturation or arousal
    Central event duration noteDuration criteria differ for central events compared to obstructive events
    ApplicationUse pediatric scoring criteria when interpreting pediatric PSG to assign severity
    inv-226: Pediatric OSA severity cutoffs
    Pediatric OSA severity cutoffsMild: 1 to <5 events/hr; Moderate: ≥5 to <10 events/hr; Severe: ≥10 events/hr
    Diagnostic requirementPSG must demonstrate ≥1 obstructive apnea, mixed apnea, or hypopnea per hour to establish pediatric OSA diagnosis
    Associated clinical findingsDiagnosis supported by symptoms (snoring, witnessed apnea, behavioral issues) plus one objective related finding (tonsillar hypertrophy, failure to thrive, etc.)
    inv-227: Hypoglossal nerve stimulator (HGNS) definition
    Hypoglossal nerve stimulator (HGNS)Surgically implanted device delivering electrical pulses to hypoglossal nerve to activate upper airway musculature, often synchronized to ventilatory effort via a sensing lead
    Therapy contextHGNS considered for moderate‑to‑severe OSA in patients intolerant of PAP after required trials and testing per guidelines
    Pre/post‑implant testingPre‑implant HSAT and PAP trial recommended; in‑lab PSG criteria apply for candidacy and post‑implant optimization
    inv-228: Transvenous phrenic nerve stimulator (TPNS) definition
    Transvenous phrenic nerve stimulator (TPNS)Implantable device that stimulates a phrenic nerve to produce diaphragmatic breaths to treat central sleep apnea (e.g., Remede System)
    Pre‑implant PSG criteriaAdult age ≥18; moderate‑to‑severe CSA (central AHI ≥15/hr); exclusion of transient causes; prior PAP contraindication/failure/intolerance after ≥3‑month trial; supplemental O2 contraindicated/ineffective/not tolerated
    Evaluation oversightEvaluation should be by or in consultation with a board‑eligible/certified sleep medicine physician
    inv-229: Remede System / TPNS
    Remede System / TPNSAn implantable neurostimulator and lead system that transvenously stimulates a phrenic nerve to produce diaphragmatic breaths; FDA PMA approved for moderate‑to‑severe CSA
    Trial inclusion metricsPivotal trial used entry criteria such as AHI ≥20, central AI ≥50% and ≥30 central events; post‑market studies used central AHI ≥15/hr
    Post‑implant monitoringDevice activation and follow‑up include PSG/HSAT at scheduled intervals per device pathways for efficacy and optimization
    inv-230: Moderate to severe CSA operational definition
    Operational moderate‑to‑severe CSAOperationally defined as central AHI ≥15 events/hour for many criteria; pivotal trials used higher thresholds (eg AHI ≥20 with central AI ≥50% and ≥30 central events)
    Device trial differencesDevice trial enrollment criteria may differ from operational guidance used for clinical coverage decisions
    Clinical implicationModerate‑to‑severe CSA thresholds guide candidacy for TPNS/ASV and other interventions
    inv-231: Treatment-Emergent Central Sleep Apnea (restated)
    Treatment‑emergent CSA (restated)Predominantly obstructive AHI/RDI or AHI/REI ≥5 with PSG during PAP showing resolution of obstructive events but central index ≥5/hr and central events >50% of total
    Required PSG conditionPSG during PAP without backup rate demonstrating the described pattern is required for diagnosis
    RelevanceMay necessitate ASV or other device therapy per guidelines
    inv-232: Sleep-related hypoventilation (restated)
    Sleep‑related hypoventilation (restated)PCO2 >55 mmHg for ≥10 minutes OR ≥10 mmHg increase to >50 mmHg for ≥10 minutes during sleep
    Measurement optionsArterial PaCO2, EtPCO2, TcPCO2 acceptable; VBG thresholds also used in some contexts
    Clinical useDefines need for ventilatory support or advanced PAP device initiation
    inv-233: Obesity hypoventilation syndrome (restated)
    OHS definition (restated)BMI ≥30 kg/m2 PLUS either awake ABG/EtPCO2/TcPCO2 PCO2 ≥45 mmHg OR VBG PCO2 ≥50 mmHg
    Serum bicarbonate roleSerum bicarbonate ≥27 mmol/L has high NPV for hypercapnia; when <27, hypercapnia unlikely in low–moderate pretest probability
    Clinical criteriaAdditional clinical features (recent hospitalization with persistent hypoventilation, ongoing hypoventilation despite CPAP) factored into device initiation decisions
    inv-234: General AHI/RDI/REI threshold note
    General AHI/RDI/REI threshold noteAHI/RDI/REI numeric thresholds (≥5, ≥15) are used across definitions and coverage decisions; context (symptoms, comorbidities) modifies interpretation
    Minimum event threshold≥5 events/hr often marks diagnostic consideration when symptoms present or for CSA definitions
    Severe threshold≥15 events/hr commonly used to define OSA severity for many coverage actions
    inv-241: PAP-NAP definition and coverage note
    PAP‑NAP definition and coverage notePAP‑NAP is a daytime abbreviated cardiorespiratory study (CPT 95807/95807‑52) intended to improve PAP adherence; CPT 95807/95807‑52 for PAP‑NAP is not covered due to insufficient evidence
    Reason for exclusionLack of controlled studies demonstrating benefit; pilot data insufficient
    Coding implicationRequests using CPT 95807 or 95807‑52 for PAP‑NAP will not be approved under these guidelines
    inv-242: Actigraphy definition and coverage note
    Actigraphy definition and stanceWrist‑worn movement recording estimating sleep parameters (CPT 95803); considered not medically necessary when performed as a stand‑alone study
    HSAT contextActigraphy may be part of some HSAT devices but standalone actigraphy is excluded for diagnostic use
    Coding implicationCPT 95803 as stand‑alone study is not supported for routine sleep apnea evaluation
    inv-243: LCD definition
    LCD definitionLocal Coverage Determination (LCD): Medicare policy documents cited that may impose additional device/service coverage rules
    Referenced LCDsExamples cited include LCDs for Hypoglossal Nerve Stimulation, Respiratory Assist Devices, Outpatient Sleep Studies
    ImplicationCompliance with applicable LCDs may be required for coverage decisions
    inv-244: OHS references
    OHS referencesATS guidance: serum bicarbonate <27 mmol/L effectively rules out hypercapnia in low–moderate pretest probability; consider PaCO2 measurement when suspicion higher
    Serum bicarbonate performanceSerum bicarbonate sensitivity 86–92%, specificity 50–90%; high NPV (~96%) to exclude hypercapnia
    Clinical recommendationMeasure PaCO2 when pretest probability for OHS is moderate–high even if bicarbonate ≥27
    inv-245: Upper Airway Stimulation (UAS) definition/reference
    Upper Airway Stimulation (UAS) definition/referenceUAS (HGNS) devices deliver hypoglossal nerve stimulation to activate upper airway muscles; FDA PMA/SSED documents cited (Inspire UAS) relevant to candidacy and outcomes
    Device evidenceSTAR trial and subsequent FDA approvals expanded eligibility criteria (AHI ranges, BMI limits) documented in SSED/PMA materials
    Clinical implicationPre/post‑implant testing and candidacy criteria referenced to device regulatory documentation

    Revision History and References

    2026-11-05policy_effective_dateLatest

    Policy effective date for eviCore Sleep Disordered Breathing Diagnosis and Treatment Guidelines (SL.AD.100.A v2.0.2026).

    2025-11-15reference_added

    Remede® System patient pathway citation added to references supporting TPNS content.

    2024-12-20regulatory_reference

    Zepbound (tirzepatide) FDA approval letter (12/20/2024) cited in references relevant to pre-treatment testing guidance.

    2024-11-15reference_added

    remedē System patient pathway (published Nov 15, 2023) accessed Nov 15, 2024 and cited in the guideline references.

    2019-02-15evidence_reference

    AASM systematic review and meta-analysis on PAP therapy (Patil et al., 2019) included in references to support PAP-related recommendations.